PMGC Holdings subsidiary A&B Aerospace signs long-term pact with PAD Group

PMGC Holdings Inc. (NASDAQ: ELAB) has entered into a long-term manufacturing agreement through its wholly owned subsidiary, A&B Aerospace, Inc., with Precision Aerospace & Defense Group, Inc. ("PAD Group"). Announced on July 28, 2026, the deal positions A&B Aerospace to manufacture and supply precision-machined components for aerospace and defense programs, expanding PMGC’s footprint in the U.S. defense industrial base without guaranteeing minimum purchase volumes.

The agreement, effective July 23, 2026, establishes a two-year framework that automatically renews for successive one-year periods unless either party provides notice of non-renewal. Under the terms, PAD Group and its subsidiaries may issue purchase orders to A&B Aerospace for precision-manufactured components supporting various aerospace and defense programs. Each purchase order will specify products, quantities, pricing, delivery schedules, and other requirements. Notably, the agreement does not include a guaranteed minimum purchase volume or revenue commitment.

Strategic Context and Regulatory Compliance

The agreement positions A&B Aerospace to support purchase orders associated with U.S. federal government prime contracts. These orders are subject to the Federal Acquisition Regulation (FAR) and the Defense Federal Acquisition Regulation Supplement (DFARS) requirements incorporated into the relevant purchase orders. Management stated that this framework expands A&B Aerospace’s addressable opportunity within the U.S. defense sector, where demand for qualified, U.S.-based precision manufacturing capacity continues to grow across aircraft, defense systems, and mission-critical component programs.

Agreement Details	Description
Parties	A&B Aerospace, Inc. and Precision Aerospace & Defense Group, Inc.
Effective Date	July 23, 2026
Term	Two years, auto-renewing annually
Commitment Type	No minimum volume or revenue guarantee
Regulatory Framework	FAR and DFARS compliant

Platform Validation and Future Outlook

The agreement reflects continued commercial momentum across PMGC's precision manufacturing platform, which currently includes A&B Aerospace, AGA Precision Systems, and SVM Machining. The Company believes the relationship validates the high-tolerance CNC machining, complex assembly, and engineered component capabilities of its operating companies. It demonstrates the platform's ability to win long-term programs with aerospace and defense customers that require rigorous quality systems, reliability, and on-time delivery.

PMGC expects to pursue additional long-term agreements and program awards across its manufacturing subsidiaries as it continues to scale its aerospace and defense footprint. The proposed investment and service agreement remain subject to the completion of due diligence, negotiation and execution of definitive agreements, required corporate approvals, and other customary closing conditions. There can be no assurance that the proposed investment or service agreement will be completed on the terms contemplated, or at all.

What the Numbers Show

The structure of this agreement—long-term framework without minimum volume commitments—shifts the immediate risk toward execution and order acquisition rather than guaranteed revenue floors. By securing a durable relationship with PAD Group, PMGC gains access to federal government prime contracts subject to strict FAR and DFARS regulations. This suggests that PMGC views PAD Group not just as a source of incremental volume, but as a strategic gateway into the broader U.S. defense supply chain, leveraging its existing capabilities in high-tolerance CNC machining to capture growth in mission-critical component programs.

PMGC Holdings Inc. (Nasdaq: ELAB) shares rose 14.06% to $1.20 on Friday as the company advanced its engineered probiotic platform. The gain follows an announcement from its subsidiary, NorthStrive Biosciences Inc., regarding plans to initiate an independent flow cytometry study. This move aims to characterize the EL-22 candidate, designed to preserve muscle during weight loss treatments involving GLP-1 receptor agonists.

EL-22 Characterization Study

The independent study will quantify myostatin antigen expression on Lactobacillus casei. This analysis supports comparability against materials previously manufactured by MOA Life Plus Co. Ltd., enhancing product identity and manufacturing consistency for EL-22. The initiative is part of PMGC Holdings' broader focus on biopharmaceutical innovation in obesity and metabolic health.

Strategic Context

PMGC Holdings operates in Medical Aesthetics and Biopharmaceutical Innovation, with a specialization in Skin Aesthetics, Obesity, and Metabolic Health. The company's focus on engineered probiotics positions it in the biopharmaceutical space, targeting muscle preservation during weight loss. Recent developments in product characterization are crucial for meeting regulatory standards and enhancing market position.

Business Overview

PMGC Holdings is leveraging its EL-22 platform to address significant health issues. The strategic focus on innovation is intended to drive future growth and investor interest. The company's efforts to ensure manufacturing consistency and product identity are key steps in its commercialization strategy.